Want to join the conversation?
$GILD's non-GAAP R&D expenses were $713MM in 3Q15, up 22% vs. last year due to the continued progression and expansion of its clinical studies, particularly its HIV based program. Further SG&A expenses were down 4% YoverY to $850MM, primarily due to a cumulative catch-up of the branded prescription drug fee recorded in the same period in 2014.
Any idea why some investors are happy about the disastrous $UA results??
Wow! GM killed it with earnings today! Did not expect this after $F gave the feeling it will eclipse the Chevy maker completely!
Oil rebound starting to show up in energy stocks. $XOM $CVX
I have a feeling "CLOUDy" days are ahead, with $AMZN leading the pack.
$AAL is giving pay hikes to its employees but investors are sulking.